Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Increase in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totalling 47,100 shares, an increase of 20.8% from the May 31st total of 39,000 shares. Approximately 10.7% of the company’s stock are sold short. Based on an average daily trading volume, of 28,400 shares, the short-interest ratio is currently 1.7 days.

Windtree Therapeutics Price Performance

Shares of Windtree Therapeutics stock opened at $3.20 on Tuesday. Windtree Therapeutics has a 1 year low of $2.89 and a 1 year high of $30.06. The firm has a market cap of $1.89 million, a price-to-earnings ratio of -0.09 and a beta of 0.56. The company has a 50-day moving average of $3.91 and a 200 day moving average of $6.71.

Windtree Therapeutics (NASDAQ:WINT) last announced its earnings results on Tuesday, April 16th. The company reported ($13.31) earnings per share for the quarter. On average, equities analysts anticipate that Windtree Therapeutics will post -24.93 EPS for the current year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.